In the battle between two Kit/PDGFRα kinase inhibitors first blood goes to Blueprint’s avapritinib.
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?